[go: up one dir, main page]

UA89201C2 - Энантиомеры выбранных конденсированных пиримидонов и их применение для лечения и профилактики злокачественного новообразования - Google Patents

Энантиомеры выбранных конденсированных пиримидонов и их применение для лечения и профилактики злокачественного новообразования

Info

Publication number
UA89201C2
UA89201C2 UAA200702661A UAA200702661A UA89201C2 UA 89201 C2 UA89201 C2 UA 89201C2 UA A200702661 A UAA200702661 A UA A200702661A UA A200702661 A UAA200702661 A UA A200702661A UA 89201 C2 UA89201 C2 UA 89201C2
Authority
UA
Ukraine
Prior art keywords
cancer
treatment
enantiomers
prevention
selected fused
Prior art date
Application number
UAA200702661A
Other languages
English (en)
Ukrainian (uk)
Inventor
Брайан Акила
Майкл Говард Блок
Одри ДЕЙВИС
Джеяхандран Эжутхачан
Тимоти Понц
Дениэл Джон Расселл
Марие-Елена Теоклитоу
СяоЛань Чжен
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37904998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA89201(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of UA89201C2 publication Critical patent/UA89201C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Данное изобретение касается новых соединений, которые имеют структурную формулу (И), (I)и их фармацевтических композиций и способов их применения.Эти новые соединения обеспечивают лечение или профилактику злокачественного новообразования.
UAA200702661A 2004-08-18 2005-08-16 Энантиомеры выбранных конденсированных пиримидонов и их применение для лечения и профилактики злокачественного новообразования UA89201C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60236604P 2004-08-18 2004-08-18

Publications (1)

Publication Number Publication Date
UA89201C2 true UA89201C2 (ru) 2010-01-11

Family

ID=37904998

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200702661A UA89201C2 (ru) 2004-08-18 2005-08-16 Энантиомеры выбранных конденсированных пиримидонов и их применение для лечения и профилактики злокачественного новообразования

Country Status (18)

Country Link
US (3) US20080293744A1 (ru)
EP (1) EP1781674A1 (ru)
JP (1) JP2008509977A (ru)
KR (1) KR20070046176A (ru)
CN (1) CN101027309B (ru)
AU (1) AU2005273705B8 (ru)
BR (1) BRPI0514390A (ru)
CA (1) CA2575188A1 (ru)
IL (1) IL180810A0 (ru)
MX (1) MX2007001953A (ru)
MY (1) MY141233A (ru)
NO (1) NO20071005L (ru)
RU (1) RU2447077C2 (ru)
SA (1) SA05260258B1 (ru)
TW (1) TW200616977A (ru)
UA (1) UA89201C2 (ru)
UY (1) UY29070A1 (ru)
ZA (1) ZA200701082B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716334A1 (en) * 2007-11-13 2009-05-22 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
HRP20140754T2 (hr) * 2009-06-29 2015-07-17 Incyte Corporation Pirimidinoni kao inhibitori pi3k
LT3196202T (lt) 2011-09-02 2019-07-10 Incyte Holdings Corporation Heterociklilaminai, kaip pi3k slopikliai
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
EA201691872A1 (ru) 2014-03-19 2017-04-28 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN117736209A (zh) 2015-02-27 2024-03-22 因赛特控股公司 Pi3k抑制剂的盐及其制备方法
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2023375675A1 (en) * 2022-11-10 2025-06-05 Ribometrix, Inc. COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792767A (en) 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
TR199801813T2 (xx) 1996-03-11 1998-12-21 Novartis Ag B�cek �ld�r�c� olarak pirimidin-4- on t�revleri.
WO2000039131A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company Nitrogen containing heterobicycles as factor xa inhibitors
WO2001019800A2 (en) 1999-09-16 2001-03-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP1686120A3 (en) 1999-10-27 2007-05-30 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
BR0116096A (pt) 2000-12-11 2005-10-18 Tularik Inc Composto, composição farmacêutica, e, métodos para tratar uma condição ou doença inflamatória ou imune em um paciente, para tratar uma condição ou doença mediada por cxcr3 em um paciente, e para a modulação da função de cxcr3 em uma célula
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
EP1372657A4 (en) 2001-03-29 2005-11-09 Bristol Myers Squibb Co METHOD FOR THE TREATMENT OF PROLIFERATIVE DISEASES USING EG5-INHIBITORS
US20030096813A1 (en) 2001-04-20 2003-05-22 Jingrong Cao Compositions useful as inhibitors of GSK-3
US7060705B2 (en) * 2001-11-07 2006-06-13 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003043995A1 (en) * 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
JP4391825B2 (ja) 2001-12-06 2009-12-24 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
US7378411B2 (en) 2001-12-06 2008-05-27 Merck & Co., Inc. Substituted thienopyrimidinones as a mitotic kinesin inhibitor
CA2467916A1 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1481077B1 (en) * 2001-12-06 2009-11-04 Merck & Co., Inc. Mitotic kinesin inhibitors
US7244723B2 (en) * 2001-12-06 2007-07-17 Merck & Co., Inc. Substituted furopyrimidinones as a mitotic kinesin inhibitors
US7009049B2 (en) 2002-02-15 2006-03-07 Cytokinetics, Inc. Syntheses of quinazolinones
CN100381437C (zh) * 2002-04-17 2008-04-16 赛特凯恩蒂克公司 化合物、组合物和方法
US7166595B2 (en) * 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
US7214800B2 (en) * 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
US7038048B2 (en) * 2002-05-23 2006-05-02 Cytokinetics, Inc. 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use
CA2485343A1 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2003231799A1 (en) 2002-05-23 2003-12-12 Merck & Co., Inc. Mitotic kinesin inhibitors
US7041676B2 (en) 2002-06-14 2006-05-09 Cytokinetics, Inc. Compounds, compositions, and methods
DE60326248D1 (de) * 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
JP2006501201A (ja) 2002-07-23 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
EP1539180A4 (en) 2002-08-21 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
WO2004024086A2 (en) 2002-09-13 2004-03-25 Cytokinetics, Inc. Compounds, compositions and methods
EP1558083A4 (en) 2002-09-30 2008-04-16 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
AU2003300031A1 (en) 2002-10-11 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
MXPA05003830A (es) 2002-10-11 2005-06-23 Cytokinetics Inc Compuestos, composiciones y metodos.
US20070149500A1 (en) 2003-01-17 2007-06-28 Han-Jie Zhou Compounds, compositions, and methods
AR050920A1 (es) 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
JP3947758B2 (ja) 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用
EP1622883A4 (en) 2003-04-10 2008-04-02 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
WO2004100873A2 (en) 2003-05-07 2004-11-25 Cytokinetics, Inc. Compounds, compositions, and methods
JP2006526017A (ja) 2003-05-14 2006-11-16 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
JP2007500746A (ja) 2003-05-15 2007-01-18 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
AU2004249730A1 (en) * 2003-06-20 2004-12-29 Novartis Vaccines And Diagnostics, Inc. Pyridino(1,2-A)pyrimidin-4-one compounds as anticancer agents
US20050165089A1 (en) * 2003-10-06 2005-07-28 Gustave Bergnes Compounds, compositions and methods
EP1680420A4 (en) * 2003-11-07 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
SG148202A1 (en) 2003-11-25 2008-12-31 Novartis Vaccines & Diagnostic Quinazolinone compounds as anticancer agents
EP1692112A4 (en) 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
US7501416B2 (en) * 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
JP4895220B2 (ja) 2004-04-06 2012-03-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キネシン有糸分裂インヒビター
WO2005113507A1 (en) 2004-05-21 2005-12-01 Novartis Vaccines And Diagnostics Inc. Substituted quinoline derivatives as mitotic kinesin inhibitors
US7576221B2 (en) 2004-06-18 2009-08-18 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivatives
US20060041128A1 (en) 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
CN101023086A (zh) 2004-08-18 2007-08-22 阿斯利康(瑞典)有限公司 选择性稠合的杂环及其应用
CA2584979A1 (en) * 2004-10-19 2006-05-11 Novartis Vaccines And Diagnostics, Inc. Indole and benzimidazole derivatives

Also Published As

Publication number Publication date
UY29070A1 (es) 2006-03-31
BRPI0514390A (pt) 2008-06-10
JP2008509977A (ja) 2008-04-03
KR20070046176A (ko) 2007-05-02
NO20071005L (no) 2007-05-16
US7498333B2 (en) 2009-03-03
MY141233A (en) 2010-03-31
US20060041129A1 (en) 2006-02-23
TW200616977A (en) 2006-06-01
MX2007001953A (es) 2007-05-09
RU2007109866A (ru) 2008-09-27
US20090099210A1 (en) 2009-04-16
CA2575188A1 (en) 2006-02-23
CN101027309B (zh) 2010-10-27
EP1781674A1 (en) 2007-05-09
CN101027309A (zh) 2007-08-29
RU2447077C2 (ru) 2012-04-10
AU2005273705A1 (en) 2006-02-23
ZA200701082B (en) 2008-07-30
AU2005273705B8 (en) 2010-01-28
IL180810A0 (en) 2007-06-03
AU2005273705B2 (en) 2009-12-10
US20080293744A1 (en) 2008-11-27
SA05260258B1 (ar) 2009-12-22

Similar Documents

Publication Publication Date Title
MXPA05009885A (es) Nuevas triazolonas fusionadas y los usos de las mismas.
TW200800963A (en) Chemical compounds
SI1853602T1 (sl) Kemične spojine
SI1853588T1 (sl) Kemične spojine
IL260127B (en) mek inhibitors and methods of using them
TW200714604A (en) Substituted heterocycles and the uses thereof
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
TNSN06228A1 (en) Compounds and methods of use
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
EP2400847A4 (en) SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOINE COMPOUNDS
TW200510427A (en) Novel fused heterocycles and uses thereof
UA89201C2 (ru) Энантиомеры выбранных конденсированных пиримидонов и их применение для лечения и профилактики злокачественного новообразования
TW200738659A (en) Novel compounds
PL1809288T3 (pl) Zastosowanie pochodnych 1,4-bis-(3-aminoalkilo)piperazyny do leczenia chorób neurodegeneracyjnych
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
TW200700064A (en) Novel compounds
TW200736227A (en) New compounds III
GB0407025D0 (en) Novel compounds
MX2007001954A (es) Heterociclicos fusionados seleccionados y sus usos.
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
TW200720262A (en) Novel compounds ii
TW200745133A (en) New compounds II